Elliott F. Winton - Concepedia

Author

Elliott F. Winton

Emory University

Also Known As

E F Winton, ELLIOTT F. WINTON, Elliott F Winton, Elliott F. Winton, Elliott Winton, Moshe Talpaz

120

Publications

6.4K

Citations

H-Index

Concepts

All Affiliations

Emory University The University of Texas MD Anderson Cancer Center University of Utah University of Michigan Incyte (United States)

About

Elliott F. Winton is an author at Emory University specializing in medicine, hematology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	20	1.9K
2	Health Sciences	8	8	837
3	Allergy	2	2	22
4	Public Health	1	1	93
5	Biochemistry	1	1	39

Elliott F. Winton

Publications

5.7K

Citations

H-Index

Page 1

	Year	Citations
A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis Srđan Verstovšek, Ruben A. Mesa, Jason Gotlib, New England Journal of Medicine	2012	2K
SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor–Naïve Patients With Myelofibrosis Ruben A. Mesa, Jean‐Jacques Kiladjian, John Catalano, Journal of Clinical Oncology Hematological MalignancyImmunohematologyMomelotinib 200Health SciencesPediatric Hematology	2017	345
Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study Claire Harrison, Nicolaas Schaap, Alessandro M. Vannucchi, The Lancet Haematology Hematological MalignancyAntifibrotic TherapyOncologyMulticentre StudyHematology	2017	316
Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial Claire Harrison, Alessandro M. Vannucchi, Uwe Platzbecker, The Lancet Haematology Hematological MalignancyMomelotinib VersusSimplify 2HematologyPharmacotherapy	2017	301
CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl–positive human leukemia cells to apoptosis due to antileukemic drugs Guofu Fang, Caryn Naekyung Kim, Charles Perkins, Blood	2000	260
Effect of Ruxolitinib Therapy on Myelofibrosis-Related Symptoms and Other Patient-Reported Outcomes in COMFORT-I: A Randomized, Double-Blind, Placebo-Controlled Trial Ruben A. Mesa, Jason Gotlib, Vikas Gupta, Journal of Clinical Oncology	2013	189
A controlled study of the efficacy of granulocyte transfusions in patients with neutropenia William R. Vogler, Elliott F. Winton The American Journal of Medicine ImmunohematologyGranulocyteTransfusion MedicineHematologyMedicine	1977	183
Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea Abdulraheem Yacoub, John Mascarenhas, Heidi Kosiorek, Blood	2019	165
Acquired Copper Deficiency: A Potentially Serious and Preventable Complication Following Gastric Bypass Surgery Daniel Griffith, David Liff, Thomas R. Ziegler, Obesity ObesityMetabolic SyndromeRygb ProceduresMetabolic DisorderBioactive Metal	2009	156
Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial Daniel J. DeAngelo, Deepti Radia, Tracy I. George, Nature Medicine	2021	139

Page 1